600141.Ss
The company operates in the Commodity Chemicals industry, producing and selling chemical products, primarily generating revenue through the sale of these goods.
Business. The company operates in the Commodity Chemicals industry, producing and selling chemical products, primarily generating revenue through the sale of these goods.
Analyst recommendations
7 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Commodity Chemicals industry, producing and selling chemical products, primarily generating revenue through the sale of these goods.
The company's capital structure is characterized by a debt-to-equity ratio of 0.76, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.6, suggesting potential short-term liquidity constraints. The company's price-to-book ratio of 1.85 and price-to-tangible-book ratio of 1.85 reflect a market valuation that is in line with its book value.
In terms of profitability, the company's return on equity (ROE) of 6.78% and return on assets (ROA) of 2.87% are below the typical thresholds for strong performance in the Commodity Chemicals industry. The gross profit margin of 16.51% and operating margin of 7.89% also indicate that the company is generating profits, but at a rate that may not be sufficient to outperform industry peers.
The company's revenue is primarily concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher risks associated with market fluctuations in its primary operating region.
The company's growth trajectory is expected to remain stable, with no significant changes in revenue projected for the current and next fiscal years. The capital expenditure of -2.25 billion CNY suggests a reduction in investment in new projects or facilities, which may impact long-term growth potential.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag that may affect the company's ability to meet short-term obligations.
Recent events, including analyst estimates and price targets, suggest a generally positive outlook from the investment community. The mean price target of 34.80 CNY and a mean recommendation of 1.57 indicate that analysts are cautiously optimistic about the company's future performance.
- The company has a moderate debt-to-equity ratio, indicating a balanced capital structure.
- The company's profitability metrics are below industry benchmarks, suggesting room for improvement.
- The company's revenue is concentrated in a single segment, increasing exposure to market risks.
- Analysts have a cautiously optimistic outlook, with a mean price target slightly above the current market price.
- "margin_outlook_rationale": "The company's gross and operating margins are stable but not exceptional, indicating a need for cost optimization to improve profitability.",
- "rd_outlook_rationale": "The company's R&D spending is not disclosed, but the lack of significant capital expenditure suggests limited investment in innovation.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,91 |
| Revenue | —no estimate | —no estimate | 31,4B CNY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 600141.SS Market data — financials · 2026-05-27
- Hubei Xingfa Chemicals Group Co Ltd Market data — analyst estimates · 2026-05-27